Backgrounds: In this study, we evaluated the factors associated with a pathologic complete respon... more Backgrounds: In this study, we evaluated the factors associated with a pathologic complete response (pCR) after neoadjuvant chemoradiotherapy (nCRT) for esophageal squamous cell carcinoma (ESCC). Methods: Pre-nCRT parameters in ESCC patients treated between 1999 and 2006 were analyzed to identify predictors of pCR. All patients received 5-fluorouracil/cisplatin-based chemotherapy and external beam radiation followed by scheduled esophagectomy. Variables were analyzed using univariate and multivariate analyses with pCR as the dependent variable. Estimated pCR rate was calculated with a regression model. Results: Fifty-nine (20.9%) of 282 patients achieved pCR. Univariate analysis identified four patient factors (age, smoking status, drinking history and hypertension), one pre-nCRT parameter (tumor length) as significant predictors of pCR (all P <0.05). On multivariate analysis, tumor length ≤3 cm (favorable, odds ratio (OR): 4.85, P = 0.001), patient age >55 years (favorable, OR: 1.95, P = 0.035), and being a non-smoker (favorable, OR: 3.6, P = 0.003) were independent predictors of pCR. The estimated pCR rates based on a logistic regression including those three predictors were 71%, 35 to approximately 58%, 19 to approximately 38%, and 12% for patients with 3, 2, 1 and 0 predictors, respectively. Age, smoking habit and tumor length were important pCR predictors. These factors may be used to predict outcomes for ESCC patients receiving nCRT, to develop risk-adapted treatment strategies, and to select patients who could participate in trials on new therapies.
Medical journal of clinical trials & case studies, 2020
Crizotinib is a tyrosine kinase inhibitor approved for use in the treatment of anaplastic lymphom... more Crizotinib is a tyrosine kinase inhibitor approved for use in the treatment of anaplastic lymphoma kinase positive, advanced non-small cell lung cancer. This targeted therapy improved clinical outcome and prolonged responses. However, potentially serious adverse effects may occur. We report a case of Crizotinib-induced large bowel perforation.
Non-small cell lung cancer (NSCLC) is the leading cause of cancer death. The identification of on... more Non-small cell lung cancer (NSCLC) is the leading cause of cancer death. The identification of oncogenetic driver mutation in lung cancer led to a therapeutic revolution by the discovery of targetable genetic alterations including the anaplasic lymphoma kinase (ALK) fusion oncogene and ROS1 . The tyrosine kinase inhibitor "Crizotinib" improved clinical outcome and prolonged responses. Severe hepatotoxicity is a rare adverse event .We report a case of Crizotinib-induced acute hepatitis with a probable drug-bergamot interaction.
Objective: The aim of this study was to present a case of hepar lobatum resulting from metastatic... more Objective: The aim of this study was to present a case of hepar lobatum resulting from metastatic rectal carcinoma. Clinical Presentation and Intervention: A 50-year-old man presented with a 2-year history of bleeding per anum, tenesmus, malaise and weakness. Initially, the patient received neoadjuvant chemoradiotherapy followed by abdominoperineal resection of the rectum. Abdominal computed tomography showed lobar enlargement and lobulated contour, mainly in the left lobe of the liver, but no primary or metastatic lesions were detected. Laparotomy revealed an irregularly lobulated hepatic deformity. Liver biopsy showed a necrotic tumor growth from adenocarcinoma of the rectum in subcapsular localizationof the liver. Conclusion: This case showed a patient with hepar lobatum carcinomatosum caused by metastatic rectal carcinoma. The report further highlights the need for clinicians and surgeons to keep in mind the possibility of hepar lobatum carcinomatosum while caring for rectal car...
Uploads
Papers by Yosr ZENZRI